Compare
ANI Pharmaceuticals vs Johnson & Johnson (ANIP vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year ANI Pharmaceuticals (ANIP) returned -27.2% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are -14.6% and +33.5%.
Johnson & Johnson is the larger company by market value, about 455.4 times the size of ANI Pharmaceuticals.
On trailing earnings, ANIP trades at 13.5 times and JNJ at 41.9 times.
Revenue grew +25.9% at ANIP and +7.8% at JNJ over the last year.
ANIP pays no dividend. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| ANIP | JNJ | |
|---|---|---|
| Price | $67.41 | $276.22 |
| 1-day | -3.17% | +1.43% |
| YTD | -14.61% | +33.47% |
| 1 year | -27.22% | +48.51% |
| 3 years | +9.33% | +85.77% |
| Market cap | $1.5B | $665.0B |
| P/E | 13.5 | 41.9 |
| P/S | 1.40 | 6.69 |
| P/B | 2.29 | 8.16 |
| Revenue growth | +25.90% | +7.80% |
| EPS growth | +207.40% | -36.40% |
| Gross margin % | 61.1 | 67.6 |
| Net margin % | 11.2 | 16.2 |
| ROE % | 18.3 | 19.7 |
| Debt / equity | 0.47 | 0.55 |
| FCF yield % | 14.1 | 3.1 |
| Dividend yield % | — | 1.91 |
| Beta | 0.29 | -0.09 |
| RSI (14) | 34.9 | 59.4 |
| Technical rating |